Aveo Pharmaceuticals, Inc.

Xoma Technology Ltd.

Xoma Technologies, Ltd.

May Han

William M Winston, Jr

Jeno Gyuris

Lyne Breault

Jie Lin

Bijan Etemad-Gilbertson

Christine Knuehl

S Kirk Wright

Arnold H Horwitz

Ting Chen

Solly Weiler

Kristan Meetze

Lorena Lerner

Steve Bottega

Sylvie Vincent

Kerry Whalen

Qing Liu

Andrea Boudrow

James Gifford

Jinwei Jiang

William M Winston

The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (HGF), in particular human HGF. The binding proteins can be used as diagnostic and/or therapeutic agents. With regard to their therapeutic activity, the binding proteins can be used to treat certain HGF responsive disorders, for example, certain HGF responsive tumors.

Nucleic acid encoding hepatocyte growth factor (HGF) binding proteins

Monoclonal antibodies that bind and inhibit activation of human RON (Recepteur d'Origine Nantais) are disclosed. The antibodies can be used to treat certain forms of cancer that are associated with activation of RON.

Anti-ron antibodies

Monoclonal antibodies that bind and inhibit activation of human RON (Recepteur d' Origine Nantais) are disclosed. The antibodies can be used to treat certain forms of cancer that are associated with activation of RON.

Anti-RON antibodies

Hepatocyte growth factor (HGF) binding proteins

[object Object]

Hepatocyte growth factor (HGF) binding antibody

Growing community of inventors

Brookline, MA, United States of America

May Han